Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecologic cancers

M P Boente1, R Schilder, R F Ozols

  • 1Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Gynecologic oncology·2007
Same author

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.

Gynecologic oncology·2006
Same author

Challenges for chemotherapy in ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Clinical trials in ovarian carcinoma: study methodology.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Treatment goals in ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
Same author

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2003
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Significant advances in ovarian cancer treatment include paclitaxel and platinum-based chemotherapy. Further research is needed to clarify optimal drug selection and the role of interval debulking surgery.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Clinical Trials

Background:

  • Ovarian cancer treatment has seen progress with paclitaxel and platinum-based chemotherapy regimens.
  • Optimal scheduling, dosing, and choice between carboplatin and cisplatin remain debated.
  • The utility of interval debulking surgery in ovarian cancer is under investigation.

Purpose of the Study:

  • To review advances in ovarian cancer chemotherapy.
  • To highlight challenges in treating cervical, endometrial, vaginal, and vulvar carcinomas.
  • To emphasize the need for robust clinical trials in gynecologic cancers.

Main Methods:

  • Review of current chemotherapy regimens for ovarian cancer.
  • Analysis of challenges in prospective-randomized trials for other gynecologic malignancies.

Related Experiment Videos

  • Discussion of future research directions in gynecologic oncology.

    • Main Results:

    • Paclitaxel and platinum-based regimens show success in ovarian cancer.
    • Lack of prospective-randomized trials hinders progress for cervical, endometrial, vaginal, and vulvar cancers.
    • Non-randomized trials offer preliminary insights but lack statistical power.

    Conclusions:

    • While ovarian cancer treatment has advanced, controversies in chemotherapy and surgery persist.
    • Progress in other gynecologic cancers is limited by insufficient high-quality clinical trials.
    • Future efforts should focus on large, collaborative national studies for definitive conclusions.